AMERICAN VANGUARD CORPAVD

時価総額

$1.1億

PER

農薬・特殊化学品の有力企業。天然油由来の生物系農薬とIPライセンスを展開。主要株主にBlackRock6.03%とVanguard5.36%、2023年10月にPunto Verdeを買収。米国・メキシコ・ブラジル・豪州など45カ国で展開。

概要財務

サマリーテーブルに戻る

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net (loss) income	-	37	34	4	6	13	20	24	14	15	19	27	8	-126
Depreciation, Depletion and Amortization, Nonproduction	14	13	15	16	16	16	17	19	19	20	22	22	22	22
Amortization of other long-term assets	-	-	-	-	-	-	-	-	4	4	4	4	2	0
Amortization and accretion of deferred loan fees and discounted liabilities	-	-	-	-	-	-	-	-	-	-0	-0	-0	-0	-1
(Gain) loss on disposal of property, plant and equipment	-	-	-	-	-	-	-	-	-	-0	-0	-0	-	1
Impairment of intangible assets	-	-	-	-	-	-	-	-	-	-	-	-	-	50
Provision for estimated credit losses	-	-	-	-	-	-	-	-	1	1	1	1	2	2
Increase (Decrease) in Deferred Compensation	-	-	-	-	-	-	-	-	-	0	1	1	-	-
Stock-based compensation	-	-	-	-	-	3	5	6	7	7	7	6	6	4
Deferred income taxes	5	-1	3	3	0	-0	0	-1	3	1	-2	-5	-10	1
Changes in liabilities for uncertain tax positions or unrecognized tax benefits	-	-	-	-	-	-	-	-	-	2	2	1	1	2
Change in equity investment fair value	-	-	-	-	-	-	-	-	-	1	-1	-1	-0	-2
Leases	-	-	-	-	-	-	-	-	-	-	-	0	0	-0
Unrealized foreign currency transaction gains	-	-	-	-	-	-	-	-	-	-	0	0	1	-1
Decrease (increase) in receivables	35	8	-2	13	-13	12	-1	21	11	-16	24	6	20	-7
Decrease (increase) in inventories	-3	17	52	26	-29	-16	-16	31	-4	-7	-8	30	27	-35
(Increase) decrease in income tax receivable	7	2	-11	4	5	1	-12	3	-7	-0	6	-5	4	-4
(Increase) decrease in prepaid expenses and other assets	2	24	20	5	-2	4	-1	-0	1	-0	3	3	-1	1
(Decrease) increase in accounts payable	8	10	8	-20	-5	9	3	9	-8	-8	9	2	-2	4
Increase Decrease In Customer Prepayments	-	-	-	-	-	-	-	-	-	-	-	-	-45	-13
Increase (Decrease) in Accrued Liabilities	-	-	-	-	-	-	-5	-2	6	-3	18	-2	7	2
Increase (Decrease) in Other Operating Liabilities	11	8	22	-5	-6	3	-4	-5	-3	-1	4	0	-	17
Decrease in contingent consideration	-	-	-	-	-	-	-	-	-	-	-	1	-	-
Net cash provided by (used in) operating activities	39	40	-6	-	-	-	-	11	9	89	86	57	-59	4
Capital expenditures	6	18	15	7	7	11	7	8	13	11	10	13	12	7
Proceeds from Sale of Property, Plant, and Equipment	-	-	-	-	-	-	-	-	-	-	-	0	0	1
Acquisitions of business and product line, net of cash acquired	-	-	-	-	-	-	82	20	42	19	10	-	5	-
Intangible assets	0	3	-	-	37	0	-	-	-	4	1	1	0	0
Net cash used in investing activities	-7	-21	-19	-	-	-	-	-28	-55	-36	-20	-14	-17	-7
Payments under line of credit agreement	-	-	-	-	-	-	-	-	-	-	-	-	-	294
Proceeds from Lines of Credit	-7	-	-	-	-	-	-	-	-	-	-	-	-	303
(Increase) in deferred loan fees	-	-	-	-	-	-	-	-	-	-	-	-	-	1
Payment of contingent consideration	-	-	-	-	-	-	-	-	-	-	1	0	-	-
Net receipt from the issuance of common stock under ESPP	-	-	-	-	-	-	-1	2	0	-0	1	1	1	1
Net receipt from the exercise of stock options	-	-	-	-	-	-	-	-	-	-	0	1	0	-
Payment from common stock purchased for tax withholding	-	-	-	-	-	-	-	-	-	-	3	2	2	1
Repurchase of common stock	-	-	2	2	-	-	-	7	3	-	5	34	16	-
Payment of cash dividends	2	6	5	6	1	1	2	2	2	1	2	3	3	3
Net cash provided by (used in) financing activities	2	-16	-7	-	-	-	-	11	46	-43	-66	-38	67	5
Net increase (decrease) in cash	-	-	-	-	-	-	-	-	1	10	0	4	-9	2
Effect of exchange rate changes on cash	-	-	-	-	-	-	-	-	-1	-1	-0	-0	0	-1